Rivus appoints Smith as chair and hires Schott as CMO

Rivus Pharmaceuticals Inc. appointed Ian Smith as chairman and hired Robert Schott as CMO. Smith is executive chairman of the board of Solid Biosciences Inc. (NASDAQ:SLDB); Schott joins Rivus from Nutcracker Therapeutics Inc., where he was CMO. Rivus also announced the first patient has been randomized in the company’s Phase IIb M-ACCEL trial of HU6, which targets the mitochondria to improve the liver fat content of obese subjects with Type II diabetes at risk of metabolic dysfunction-associated steatohepatitis.

Noema Pharma AG, which is developing four clinical neurology programs in-licensed from Roche (SIX:ROG; OTCQX:RHHBY), hired Robert Lasser as CMO. Lasser held an executive role at Sage Therapeutics Inc. (NASDAQ:SAGE)...